Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris

Clinical Cardiology

Volumn 21, Issue 7, 1998, Pages 483-490

  Frishman, William H ^a   Bittar, Neville ^b   Glasser, Stephen ^c   Habib, Gabriel ^d   Smith, William ^e   Pordy, Robert ^f  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Louisiana Cardiovascular Research Center   (United States)

^f HOFFMANN LA ROCHE INC   (United States)

Author keywords

Angina pectoris; Mibefradil; Nitrate combination

Indexed keywords

MIBEFRADIL; NITRATE;

ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031821027     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960210707     Document Type: Article

References (21)

1. Glasser S: Clinical mechanisms of nitrate action. Am J Cardiol 1998;81(1A):49A-53A
2. Frishman WH: Calcium channel blockers. In Cardiovascular Pharmacotherapeutics (Eds. Frishman WH, Sonnenblick EH), p. 101-130. New York: McGraw Hill, 1997
3. Frishman WH: Mibefradil: A new selective T-channel calcium antagonist for hypertension and angina pectoris. J Cardiovasc Pharm Therap 1997;2:321-330
4. Bernink P, Prager G, Schelling A, Kobrin I: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): A new generation of calcium antagonists? Hypertension 1996;27: 426-432
5. Bursztyn M, Kadr H, Tilvis R, Martina B, Oigman W, Talberg J, Kobrin I: Mibefradil, a novel calcium antagonist, in elderly hypertensives: Favorable hemodynamics and pharmacokinetics. Am Heart J 1997;134:238-247
6. Carney S, Wing L, Ribeiro A, Kallwellis R, Zimlichman R, Viskoper R, Mion DJ, Kobrin I: The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. J Hum Hypertens 1997; 11:387-393
7. Oparil S, Kobrin I, Abernethy D, Levine B, Reif M, Shepherd A: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens 1997;10:735-742
8. Alpert J, Kobrin I, DeQuattro V, Friedman R, Shepherd A, Fenster P: Additional anti-anginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta-blocker for chronic stable angina pectoris. Am J Cardiol 1997;79:1025-1030
9. Braun S, van der Wall E, Emanuelsson H, Kobrin I: Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study. J Am Coll Cardiol 1996;27:317-322
10. Bakx A, van der Wall E, Braun S, Emanuelsson H, Bruschke A, Kobrin I: Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. Am Heart J 1995;130:748-757
11. Schneeweiss A, Kobrin I, Caspi A, Marmor A, Sclarovsky S, Reisin L, Schlesinger Z: Adding the new calcium antagonist mibefradil to patients on chronic beta-blocker therapy results in improved anti-anginal and anti-ischemic efficacy. Am Heart J 1998;135:272-280
12. Tzivoni D, Kadr H, Braat S, Rutsch W, Ramires J, Kobrin I: Efficacy of mibefradil in comparison to amlodipine in suppressing exercise-induced and daily silent ischemia: Results of a multicenter, placebo-controlled trial. Circulation 1997;96:2557-2564
13. Alpert J, Bakx A, Braun S, Frishman W, Schneeweiss A, Tzivoni D, Kobrin I: The anti-anginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris: Placebo-controlled studies. Am J Cardiol 1997;80:20C-26C
14. Davies MJ. Pathology of the conducting system. In Cardiology in Old Age (Eds. Caird FL, Dalle JLC, Kennedy RD), p. 57-59. New York: Plenum Publishing Corp., 1976
15. Wei JY: Use of calcium entry blockers in elderly patients: Special considerations. Circulation 1989;80(suppl IV):IV-171-IV-177
16. 2+ channel in cardiac tissue. Eur J Plarmacol 1995; 90:155-158
17. 2+ channels by RO 40-5967. Circ Res 1994;75:144-148
18. Katz A: Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 1996;28:522-529
19. Rousseau M, Hayashida W, van Eyll C, Hess O, Benedict C, Ahn S, Chapella F, Kobrin I, Pouleur H: Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolicdysfunction. J Am Coll Cardiol 1996;28:972-979
20. Orito K, Satoh K, Taira N: Cardiovascular profile of RO 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood perfused dog hearts. J Cardiovasc Pharmacol 1993; 22:293-299
21. Schmitt R, Kleinbloesem C, Belz G, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez A-J, Welker H, van Brummelen P: Hemodynamic and humoral effects of the novel calcium antagonist RO 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992;52:314-323